#	Pagina
attuale pagina	/open-h2020/projects/211191/index.html

Opendata, web and dolomites

VSV-EBOPLUS SIGNED

SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV-ZEBOV EBOLA VACCINE - Sofia ref.: 116068

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

VSV-EBOPLUS project word cloud

Explore the words cloud of the VSV-EBOPLUS project. It provides you a very rough idea of what is the project "VSV-EBOPLUS" about.

1x108 adult 2x107 vsv vector protective edge vaccination almost comprehensively continents signatures biology reactogenicity data central doses disease vesicular immunity sponsored outbreak collecting baseline blood examine recombinant trial ring pfu population correlation extremely vaccine protocols eboplus influence series 2015 safety vulnerable capitalizing replaced immunogenicity 3x103 2014 injected licensing demonstrated decipher remarkably guinea clinical glycoprotein overarching efficacy africa protection evd harmonized dose determinants strain standardized envelope adolescents interruption mode pediatric zaire benefit adults ebola zebov graded unanswered elicited initiation children days questions samples stomatitis cutting action 512 molecular immune virus proposes

Project "VSV-EBOPLUS" data sheet

The following table provides information about the project.

Coordinator	SCLAVO VACCINES ASSOCIATION Organization address address: PIAZZA LA LIZZA 7 city: SIENA postcode: 53100 website: www.sclavo.org/home contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Project website	http://www.vsv-eboplus.eu
Total cost	15˙430˙660 €
EC max contribution	8˙553˙750 € (55%)
Programme	1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
Code Call	H2020-JTI-IMI2-2015-08-single-stage
Funding Scheme	IMI2-RIA
Starting year	2016
Duration (year-month-day)	from 2016-04-01 to 2021-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	SCLAVO VACCINES ASSOCIATION SCLAVO VACCINES ASSOCIATION Organization address address: PIAZZA LA LIZZA 7 city: SIENA postcode: 53100 website: www.sclavo.org/home contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (SIENA)	coordinator	1˙625˙000.00
2	GOETEBORGS UNIVERSITET GOETEBORGS UNIVERSITET Organization address address: VASAPARKEN city: GOETEBORG postcode: 405 30 website: www.gu.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (GOETEBORG)	participant	1˙698˙750.00
3	ACADEMISCH ZIEKENHUIS LEIDEN ACADEMISCH ZIEKENHUIS LEIDEN Organization address address: ALBINUSDREEF 2 city: LEIDEN postcode: 2333 ZA website: www.lumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	participant	1˙696˙875.00
4	UNIVERSITA DEGLI STUDI DI SIENA UNIVERSITA DEGLI STUDI DI SIENA Organization address address: VIA BANCHI DI SOTTO 55 city: SIENA postcode: 53100 website: www.unisi.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (SIENA)	participant	1˙645˙000.00
5	Centre de Recherches Medicales de Lambaréné Centre de Recherches Medicales de Lambaréné Organization address address: NA city: Lambaréné postcode: 118 website: www.cermel.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	GA (Lambaréné)	participant	701˙250.00
6	MICROBIOTEC SRL MICROBIOTEC SRL Organization address address: VIA DELLE VIGNE 12 city: MONTERIGGIONI postcode: 53035 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (MONTERIGGIONI)	participant	485˙000.00
7	EBERHARD KARLS UNIVERSITAET TUEBINGEN EBERHARD KARLS UNIVERSITAET TUEBINGEN Organization address address: GESCHWISTER-SCHOLL-PLATZ city: TUEBINGEN postcode: 72074 website: www.uni-tuebingen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (TUEBINGEN)	participant	395˙625.00
8	UNIVERSIDADE DE SAO PAULO UNIVERSIDADE DE SAO PAULO Organization address address: RUA DA REITORIA 109 BUTANTA city: SAO PAULO SP postcode: 05508 900 website: www.usp.br contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BR (SAO PAULO SP)	participant	306˙250.00
9	EIDGENOSSISCHES DEPARTEMENT FUR VERTEIDIGUNG, BEVOLKERUNGSSCHUTZ UND SPORT EIDGENOSSISCHES DEPARTEMENT FUR VERTEIDIGUNG, BEVOLKERUNGSSCHUTZ UND SPORT Organization address address: BUNDESHAUS OST city: BERN postcode: CH-3003 website: http://www.vbs.admin.ch/internet/vbs/en/home/departement.html/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (BERN)	participant	0.00
10	MERCK SHARP & DOHME CORP MERCK SHARP & DOHME CORP Organization address address: ONE MERCK DRIVE city: WHITEHOUSE STATION NJ postcode: 8889 website: www.merck.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (WHITEHOUSE STATION NJ)	participant	0.00
11	UNIVERSITE DE GENEVE UNIVERSITE DE GENEVE Organization address address: RUE DU GENERAL DUFOUR 24 city: GENEVE postcode: 1211 website: www.unige.ch contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (GENEVE)	participant	0.00

Map

Project objective

The vesicular stomatitis virus (VSV)-Zaire Ebola vaccine (VSV-ZEBOV) is a recombinant vector-based vaccine in which the VSV envelope glycoprotein was replaced with the Zaire strain Ebola virus glycoprotein. Within one year of the initiation of its clinical development, the VSV-ZEBOV vaccine has demonstrated safety, immunogenicity and a remarkably high protective efficacy against Ebola Virus Disease, using a high vaccine dose (2x107 pfu) in the WHO-sponsored VSV-ZEBOV ring-vaccination trial in adults in Guinea. However, several key questions remain unanswered, including its mode of action, its correlation with protection and reactogenicity, the expected duration of protective efficacy and determinants of long-term responses, the influence of baseline immunity on vaccine “take”, and the vaccine efficacy in children - a most vulnerable population. Following the interruption of the 2014-2015 Ebola Virus Disease (EVD) outbreak, these questions, being central to the future licensing and use of VSV-ZEBOV, may not be addressed by collecting field data. The VSV-EBOPLUS project therefore proposes to use cutting-edge systems biology approaches to address these key questions, capitalizing on the unique availability of large series of extremely well defined samples from clinical vaccine studies with the VSV-ZEBOV vaccine in three different continents (Europe, Africa, US).

Specifically, the overarching objective of VSV-EBOPLUS is to comprehensively decipher the immune and molecular signatures of adult and pediatric responses elicited by VSV-ZEBOV through systems biology approaches. VSV-EBOPLUS will benefit from harmonized and standardized clinical trial protocols, in almost 1’000 adults, adolescents and children. We propose: 1) to examine early (days 0 to 7) blood samples from 512 adults injected with graded doses (from 3x103 to 1x108 pfu) of VSV-ZEBOVÍ¾

Deliverables

List of deliverables.
Distribution of samples (serum, plasma, Paxgene tubes) to partners involved in immunogenicity / transcriptomic studies	Documents, reports	2019-10-07 17:33:12

Take a look to the deliverables list in detail: detailed list of VSV-EBOPLUS deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2018	Angela Huttner, Claire-Anne Siegrist Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know? published pages: 1105-1110, ISSN: 1476-0584, DOI: 10.1080/14760584.2018.1546582	Expert Review of Vaccines 17/12	2019-10-07
2018	Donata Medaglini, Francesco Santoro, Claire-Anne Siegrist Correlates of vaccine-induced protective immunity against Ebola virus disease published pages: , ISSN: 1044-5323, DOI: 10.1016/j.smim.2018.07.003	Seminars in Immunology	2019-10-07
2018	Angela Huttner, Selidji Todagbe Agnandji, Christophe Combescure, JosÃ© F Fernandes, Emmanuel Bache Bache, Lumeka Kabwende, Francis Maina Ndungu, Jessica Brosnahan, Thomas P Monath, Barbara LemaÃ®tre, StÃ©phane Grillet, Miriam Botto, Olivier Engler, Jasmine Portmann, Denise Siegrist, Philip Bejon, Peter Silvera, Peter Kremsner, Claire-Anne Siegrist, Sanjeev KRISHNA, Marylyn M. ADDO, Stephan BECKER, Verena KRÃ„HLING, Patricia NJUGUNA, Marie-Paule KIENY, Rafi AHMED, Jenna ANDERSON, Floriane AUDERSET, Luisa BORGIANNI, Annalisa CIABATTINI, Marielle C. HAKS, Ali HARANDI, Donald Gray HEPPNER, Alice GERLINI, Donata MEDAGLINI, Tom H.M. OTTENHOFF, David PEJOSKI, Mark PAGE, Gianni POZZI, Francesco SANTORO, Sheri DUBEY, JosÃ© F. FERNANDES, Helder NAKAYA, Fiona OROURKE, Gianni POZZI, Sylvia ROTHENBERGER Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study published pages: 738-748, ISSN: 1473-3099, DOI: 10.1016/S1473-3099(18)30165-8	The Lancet Infectious Diseases 18/7	2019-10-07

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VSV-EBOPLUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VSV-EBOPLUS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

TRIC-TB (2019)

Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.